SCHEMBL24373453

SCHEMBL24373453

N#Cc1c(Br)cc2c(c1Br)CCCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.34
▸ KDM4E B2RXH2 6/20 0.34
▸ MAPT P10636 4/20 0.34
▸ HPGD P15428 3/20 0.34
▸ APOBEC3G Q9HC16 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ HSD17B10 Q99714 5/20 0.33
▸ ALOX15 P16050 3/20 0.33
▸ BPTF Q12830 2/20 0.33
▸ ALOX12 P18054 2/20 0.33
▸ MAPK1 P28482 3/20 0.33
▸ GAA P10253 3/20 0.33
▸ NSD2 O96028 1/20 0.33
▸ MAPK10 P53779 1/20 0.32
▸ HTT P42858 2/20 0.32
▸ CASP1 P29466 2/20 0.32
▸ CASP7 P55210 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29479151 1.00 ALDH1A1 (0.34) ALDH1A1KDM4EMAPTHPGDAPOBEC3G
SCHEMBL24373461 0.76 — —
SCHEMBL29478826 0.76 — —
SCHEMBL29478793 0.74 MAPK1 (0.34) MAPK1
SCHEMBL24373031 0.74 MAPK1 (0.34) MAPK1
SCHEMBL24373460 0.73 KDM4E (0.31) KDM4EMAPTGAAHTTMEN1
SCHEMBL29478851 0.73 KDM4E (0.31) KDM4EMAPTGAAHTTMEN1
SCHEMBL28228485 0.73 TSHR (0.35) ALDH1A1KDM4EMAPTGAAMEN1
SCHEMBL6228564 0.72 MEN1 (0.45) ALDH1A1KDM4EMAPTHPGDAPOBEC3G
SCHEMBL25837417 0.71 KDM4E (0.37) ALDH1A1KDM4EMAPTHPGDAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. 2024-02-22 — — US disclosed
WO-2022083569-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2022-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE KRAS, HRAS, APC ALDH1A1 1221/4885KDM4E 4694/4885MAPT 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback